THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis

Executive Summary

• Ventripoint Diagnostics announced a strategic partnership with the Nisga’a Valley Health Authority to deploy its AI‑enhanced ultrasound platform (VMS+) in remote BC communities.
• Avant Technologies formed the Insulinova joint venture for regenerative insulin therapy and secured an exclusive license for Klotho‑producing cells, expanding its pipeline into longevity therapeutics.
• Oncolytics Biotech disclosed FDA alignment on a pivotal Phase 3 trial design for pelareorep in pancreatic cancer, citing Phase 2 data that nearly doubled survival versus historical controls.
• GT Biopharma advanced to the next dose cohort in its Phase 1 study of GTB‑3650 (TriKE) targeting AML, indicating safety committee clearance for higher potency dosing.
• GoldHaven Resources completed its first drill hole at the Western Target of the Copeçal Project in Brazil, confirming a thick saprolite horizon and validating its structural model.

Key Details

• Ventripoint Diagnostics (TSXV: VPT / OTCQB: VPTDF) – Partnership with Nisga’a Valley Health Authority to install VMS+ AI software on existing 2D ultrasound units, delivering MRI‑equivalent cardiac imaging at a fraction of traditional MRI costs.
• Avant Technologies Inc. (OTCQB: AVAI) –
• Formed Insulinova JV (Nov 4) to commercialize encapsulated insulin‑producing cells for type 1 diabetes treatment.
• Secured exclusive license (Nov 18) for Klotho‑producing cell technology aimed at anti‑aging therapeutics.
• Oncolytics Biotech Inc. (NASDAQ: ONCY) –
• FDA alignment on design of pivotal Phase 3 trial for pelareorep in pancreatic cancer.
• Phase 2 results showed ~2× improvement in overall survival versus historical benchmarks.
• GT Biopharma, Inc. (NASDAQ: GTBP) –
• Initiated next dose cohort in Phase 1 trial of GTB‑3650 (Tri‑Specific NK Cell Engager) for acute myeloid leukemia, reflecting safety committee approval for higher dosing.
• GoldHaven Resources Corp. (CSE: GOH / OTCQB: GHVNF) –
• Completed first drill hole at Western Target, Copeçal Project (Nov 12).
• Intercepted a thick saprolite horizon confirming the geological model; target lies within a historically prolific gold corridor in Brazil’s Juruena Province.

Notable Quotes

• “Our VMS+ platform brings hospital‑grade cardiac imaging to the point of care, eliminating the need for costly patient travel.” – Ventripoint Diagnostics spokesperson
• “Insulinova represents a paradigm shift from managing diabetes symptoms to restoring endogenous insulin production.” – Avant Technologies CEO
• “Pelareorep’s ability to ‘paint’ tumors for immune recognition could redefine combination immunotherapy strategies.” – Oncolytics Biotech President

All forward‑looking statements are subject to risks and uncertainties; readers should consult the companies’ regulatory filings for detailed information.